Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Double-Blind, Randomized, Single-Dose Study to Evaluate the Atrial Selectivity and Safety of BMS-394136 in Subjects with Implanted Dual-Chamber Pacemakers or Defibrillators
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A1 | Experimental |
| |
| A2 | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BMS-394136 | Drug | Oral Solution, Oral, 100 mg, Single dose, 1 day. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Effect of BMS-394136 on atrial refractoriness (atrial effective refractory period) |
| Measure | Description | Time Frame |
|---|---|---|
| Effect of BMS-394136 on atrial vs ventricular refractoriness | ||
| Effect of BMS-394136 on the QTc interval | ||
| Assess the safety and tolerability of a single dose of BMS-394136 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Local Institution | Salisbury | Maryland | United States | |||
| Local Institution |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Oral Solution, Oral, 0 mg, Single dose, 1 day. |
|
| Explore the relationship between plasma concentration of BMS-394136 and refractoriness |
| Ann Arbor |
| Michigan |
| United States |
| Local Institution | Columbus | Ohio | United States |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
Not provided
Not provided